Navigation Links
VIVUS Reports Third Quarter 2009 Highlights and Financial Results
Date:11/3/2009

MOUNTAIN VIEW, Calif., Nov. 3 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its highlights and financial results for the third quarter ended September 30, 2009.

Third Quarter Highlights

In the third quarter of 2009, we announced positive results from two final, phase 3 pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the safety and efficacy of our investigational drug candidate Qnexa in more than 3,750 patients across 93 sites. The EQUIP and CONQUER studies met all primary endpoints by demonstrating statistically significant weight loss with all three doses of Qnexa, as compared to placebo. Patients taking Qnexa also achieved significant improvements in cardiovascular and metabolic risk factors including reductions in blood pressure, lipids, and blood sugar.

Highlights from the EQUIP and CONQUER studies include:

  • Average weight loss of 14.7% (37 lbs) was achieved by patients treated with Qnexa for 56 weeks in the EQUIP study;
  • FDA guidance on efficacy benchmarks for weight loss agents exceeded at all three doses of Qnexa tested in the clinical program;
  • Completion rates up to 69% were significantly higher than placebo at all three doses of Qnexa, indicating favorable tolerability; and
  • Favorable benefit/risk safety profile for Qnexa.

In the third quarter of 2009, we closed an underwritten public offering of our common stock which provided us with gross proceeds of $108.7 million from the sale of 10,350,000 shares of our common stock at a price per share of $10.50.

"The highlight of the third quarter and the year to date was the announcement of the positive results from the year-long studies of Qnexa for the treatment of obesity. The results demonstrated that patients treated with Qnexa had weight loss up to 14.7% and significant improvement in their co-morbidities. All three doses administered in the studies exceeded the FDA guidance on efficacy endpoints. Progress on the submission of the NDA for Qnexa in obesity remains on schedule and is expected by the end of 2009," stated Leland Wilson, chief executive officer of VIVUS. "Following the announcement of the positive Qnexa results, we were able to raise $108.7 million in gross proceeds from a public offering of our common stock. With the positive results from our phase 3 trials for Qnexa and a cash and investment balance in excess of $226 million at the end of the third quarter, we believe we are well positioned to meet our goals for 2009 and beyond."

Third Quarter Results

Product revenues from the sale of MUSE in the third quarter of 2009 were $4.3 million, as compared to $4.4 million in the third quarter of 2008. License and other revenue was $115,000 and $21 million in the third quarters of 2009 and 2008, respectively. The third quarter 2008 included the recognition of deferred license revenue from Evamist. Recognition of the deferred revenue from the sale of Evamist ended in May 2009. Total revenue for the third quarter of 2009 was $4.4 million, as compared to $25.5 million for the third quarter of 2008.

Operating expenses for the third quarter of 2009 were $24.8 million as compared to $22.6 million for the same period in 2008. The difference in operating expenses for the third quarter was primarily attributable to spending related to our phase 3 clinical trials of avanafil, our orally administered investigational drug candidate for the treatment of erectile dysfunction, partially offset by reduced spending on the obesity trials for Qnexa which were completed in the third quarter of 2009.

Net loss for the third quarter of 2009 was $21.1 million, or $0.30 per share, as compared to net income of $266,000, or $0.00 per share, for the third quarter of 2008.

Nine Month Results

Product revenues from the sale of MUSE for the first nine months of 2009 were $9.7 million, as compared to $10.3 million for the same period of 2008. License and other revenue was $31.7 million for the first nine months as compared to $63.1 million for 2008. The first nine months of 2008 included recognition of deferred license revenue from Evamist. Recognition of the deferred revenue from the sale of Evamist ended in May 2009. Total revenue for the first nine months of 2009 was $41.4 million, as compared to $73.4 million for 2008.

Operating expenses for the first nine months of 2009 were $80.6 million as compared to $75.7 million for the same period in 2008. The difference in operating expenses for 2009 was primarily attributable to spending related to our phase 3 clinical trials of avanafil, partially offset by reduced spending on the Qnexa program for obesity.

Net loss for the first nine months of 2009 was $41.1 million, or $0.59 per share, as compared to $3.2 million, or $0.05 per share, for 2008.

Cash, Cash Equivalents and Available-for-Sale Securities

VIVUS had cash, cash equivalents and available-for-sale securities of $226.9 million at September 30, 2009, as compared to $189.2 million at December 31, 2008. The increase in cash, cash equivalents and available-for-sale securities of $37.7 million is the net result of cash provided by financing and investing activities, including $102.7 million in net proceeds from the underwritten public offering of our common stock and $10 million in cash from the other financing received in the first nine months of 2009, partially offset by cash used for operating activities.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Note to Investors

As previously announced, VIVUS will hold a conference call and an audio webcast to discuss the third quarter financial results today, November 3, 2009, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1-877-857-6173 and outside the U.S. 1-719-325-4932. A webcast replay will be available for 30 days and can be accessed at http://ir.vivus.com/.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.

                                    VIVUS, Inc.
                   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                       (in thousands, except per share amounts)

                          Three Months Ended            Nine Months Ended
                      --------------------------   --------------------------
                      September 30, September 30,  September 30, September 30,
                              2009          2008           2009          2008
                              ----          ----           ----          ----
                        (unaudited)   (unaudited)    (unaudited)   (unaudited)
    Revenue:
       US product, net      $3,864        $3,774         $8,125        $7,785
       International
        product                456           657          1,525         2,511
       License and other
        revenue                115        21,046         31,742        63,138
                               ---        ------         ------        ------

         Total revenue       4,435        25,477         41,392        73,434

    Operating expenses:
        Cost of goods sold
         and manufacturing   2,609         2,547          8,089         8,263
        Research and
         development        17,174        15,590         57,501        54,296
        Selling, general
         and
         administrative      5,008         4,502         14,974        13,099
                             -----         -----         ------        ------

          Total operating
           expenses         24,791        22,639         80,564        75,658
                            ------        ------         ------        ------

    Income (loss) from
      operations           (20,356)        2,838        (39,172)       (2,224)

    Interest (expense)
     income, net of
     other-than-temporary
     loss on impaired
     securities               (707)       (2,567)        (1,898)       (1,008)
                              ----        ------         ------        ------

    Income (loss)
     before provision
     for income taxes      (21,063)          271        (41,070)       (3,232)

    Provision for
     income taxes               (3)           (5)            (9)          (15)
                                --            --             --           ---

         Net income
          (loss)          $(21,066)         $266       $(41,079)      $(3,247)
                          ========          ====       ========       =======


    Net income (loss)
     per share:
         Basic and
          diluted           $(0.30)        $0.00         $(0.59)       $(0.05)

    Shares used in
     per share
     computation:
         Basic              70,942        66,122         70,149        61,801
         Diluted            70,942        67,784         70,149        61,801



                                     VIVUS, Inc.
                        CONDENSED CONSOLIDATED BALANCE SHEETS
                       (in thousands, except par value amount)


                                             September 30,       December 31,
                                                     2009               2008*
                                                     ----               ----
                                               (unaudited)
    Current assets:
          Cash and cash equivalents              $127,819            $66,121
          Available-for-sale securities            99,096            121,789
          Accounts receivable, net                  2,347              4,157
          Inventories, net                          2,760              3,041
          Prepaid expenses and other assets         3,634              3,744
                                                    -----              -----
                   Total current assets           235,656            198,852
    Property and equipment, net                     6,104              6,726
    Restricted cash                                   700                700
    Available-for-sale securities                       -              1,344
                   Total assets                  $242,460           $207,622
                                                 ========           ========

    Current liabilities:
          Accounts payable                         $7,208            $17,205
          Deferred revenue                            462             31,858
          Accrued and other liabilities            14,840             14,909
                                                   ------             ------
                   Total current liabilities       22,510             63,972

    Notes payable-net of current portion           20,104             11,177
    Deferred revenue                                  914              1,260
                                                      ---              -----
                   Total liabilities               43,528             76,409
                                                   ------             ------

    Commitments and contingencies

    Stockholders' equity:
            Common stock; $.001 par value;
             shares authorized 200,000;
             shares outstanding -
             80,548 at September 30, 2009;
             69,667 at December 31, 2008               81                 70
          Additional paid-in capital              419,547            310,558
          Accumulated other comprehensive
           income                                     152                354
          Accumulated deficit                    (220,848)          (179,769)
                                                 --------           --------
                    Total stockholders' equity    198,932            131,213
                                                  -------            -------
                    Total liabilities and
                     stockholders' equity        $242,460           $207,622
                                                 ========           ========


    *The Condensed Consolidated Balance Sheet at December 31, 2008 has been
    derived from the Company's audited financial statements at that date.

    CONTACT:

    VIVUS, Inc.               Investor Relations:  The Trout Group
    Timothy E. Morris                              Brian Korb
    Chief Financial Officer                        646-378-2923
    650-934-5200
                              Media Relations:     Pure Communications, Inc.
                                                   Dan Budwick
                                                   +1-973-271-6085

SOURCE VIVUS, Inc.


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus ... justice technology solutions for public safety, investigation, corrections ... the prisons involved, it has secured the final ... (DOC) facilities for Managed Access Systems (MAS) installed. ... additional facilities to be installed by October, 2016. ...
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/9/2016)... TURKU, Finland , June 9, 2016 ... French National Police deploy Teleste,s video security solution to ensure ... France during the major tournament ... and data communications systems and services, announced today that its ... Police Prefecture to back up public safety across ...
Breaking Biology News(10 mins):